This PROTAC offer a potential alternative treatment option for patients exhibiting resistance to VHL-based degraders.392 Furthermore, CFT8634, an oral degrader, has achieved potent and selective degradation of BRD9 with a DC50 of 2 nM, effectively impairing tumor cell growth in a dose-dependent manner both in vitro and in vivo.393 It has also demonstrated synergy with pomalidomide.394 Currently, two BRD9 degraders, CFT8634 and FHD-609, are undergoing clinical trials to elucidate their therapeutic potential and safety profiles. The gene discussed is BRD9; the disease is neoplasm.